Ovarian cancer is one of the most devastating forms of cancer that affects many women. In this malignancy, the ovaries experience aberrant cell proliferation, which can infiltrate or negatively affect other organs such as the liver, lymph nodes, intestine and bladder linings, abdominal layers, and lymph nodes. Early stages of ovarian cancer are accompanied by a few vague symptoms that become more pronounced as the cancer advances. These symptoms include bloating, pelvic pain, abdominal swelling, and loss of appetite.
Due to the recent increase in ovarian cancer cases, the market for ovarian cancer medications is expanding in a highly favorable setting. Consequently, it is anticipated that the ovarian cancer medicine industry will experience rapid expansion in developed nations in the near future. In addition, the United States and the United Kingdom have high rates of ovarian cancer among women over the age of 60, based on the current pharmaceutical market situation. Comparing ovarian cancer to other malignancies of the reproductive system, it is the sixth most prevalent cancer in women and is associated with a higher mortality rate. Prevalence of ovarian cancer is typically low in women under the age of 40. Research and development associated with the detection and treatment of Ovarian Cancer is anticipated to be financially beneficial to market participants.
Top Companies in the Ovarian Cancer Drugs Industry:
1. Bristol Myers Squibb Company
Bristol Myers Squibb Company is an American multinational pharmaceutical company. It was founded in 1887 and headquartered in New York, U.S. It operates in 108 countries. In June 2023, Clinical trials for Bristol-Myers Squibb's BMS-986340, which is being developed for ovarian cancer and is now in Phase II, are ongoing.
2. Eli Lilly and Company
Eli Lilly and Company is an American pharmaceutical company, was founded in 1876 and headquartered in Indianapolis, Indiana. It operates in 18 countries. In June 2023, Eli Lilly's LY-3143921 is being developed clinically and is currently in Phase I for Ovarian Cancer and Co, likelihood of approval.
3. GlaxoSmithKline plc
GlaxoSmithKline plc is a British multinational pharmaceutical and biotechnology company. It was founded in 2000 and headquartered in England, UK. It operates across the world. In Mar 2022, a t the 2022 SGO Annual Meeting, GSK highlighted its dedication in enhancing outcomes for patients with gynecologic cancer.
4. Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. was founded in 1953 and headquartered in Beerse, Belgium. It operates in over 100 countries. In June 2023, results from an interim analysis of Cohort 1 of the Phase 3 THOR study shows comparing treatment with BALVERSA® (erdafitinib) versus chemotherapy in patients with metastatic or incurable urothelial carcinoma (UC) and specific fibroblast growth factor receptor (FGFR) gene alterations who had previously undergone treatment with an anti-programmed death ligand 1 (PD-[L]1) agent, were released by the Janssen Pharmaceutical Companies of Johnson & Johnson.
5. Novogen, Inc.
Novogen, Inc. was founded in 2008 and headquartered in Pledran, France. It operates in more than 60 countries.
6. Genentech Inc.
Genentech Inc. is an American biotechnology corporation, was founded in 1976 and headquartered in California, United States. It operates in 160 countries. In July 2020, Genentech, a member of the Roche Group, announced that the Phase III IMagyn050 study revealed that the addition of Tecentriq ® (atezolizumab) to Avastin ® (bevacizumab), paclitaxel, and carboplatin failed to meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of newly-diagnosed advanced-stage ovarian cancer. The safety of Tecentriq in combination with Avastin, paclitaxel, and carboplatin was consistent with the known safety profile of the combination, according to the data from the initial safety assessment.
7. Aetera Zenteris Inc.
Aetera Zenteris Inc. was founded in 1990 and headquartered in Quebec, Canada. It operates in the US, Canada, and Germany. In April 2023, AEZS-108, a doxorubicin LHRH targeted conjugate compound from Aeterna Zentaris Inc., will be used as a companion diagnostic for the immunohistochemical assessment of luteinizing hormone-releasing hormone (LHRH) receptor expression, according to the announcement. Ventana Medical Systems, Inc. is a member of the Roche Group. LHRH receptors are highly expressed in endometrial, ovarian, breast, bladder, prostate, and pancreatic cancers in humans.
8. Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH was founded in 1885 and headquartered in
Ingelheim, Germany. It operates in 108 countries. In May 2023, Boehringer Ingelheim International is conducting clinical trials with BI-765179, which is now in Phase I for ovarian cancer.
9. F. Hoffman-La Roche Ltd
F. Hoffman-La Roche Ltd, commonly known as Roche, is a Swiss multinational healthcare company. It was founded in and headquartered in. It operates in more than 150 countries.
Definition: A cell growth that develops in the ovaries is called ovarian cancer. The cells can penetrate and obliterate healthy biological tissue and reproduce swiftly.
